Embolization of Liver Hemangioma: A Minimally Invasive Alternative to Surgery

EXOPHYTIC LIVER HEMANGIOMA CT

Hepatic hemangiomas are the most common benign liver tumours, often discovered incidentally on imaging. Most never need treatment — but giant hemangiomas (typically over 10

cm) that cause pain, pressure symptoms, or continue growing may need intervention, and transarterial embolization has emerged as a safer, minimally invasive alternative to surgical resection.

How Transarterial Embolization Works

A catheter is guided through the femoral or radial artery into the hepatic artery branches that supply the hemangioma, using real-time X-ray (fluoroscopic) guidance. An emulsion — most commonly a mixture of the chemotherapeutic agent bleomycin and lipiodol (an oily contrast agent that helps the emulsion stay concentrated within the tumour's abnormal vessels) — is injected directly into the feeding arteries. This is often called transarterial bleomycin–lipiodol embolization or chemoembolization (TACE).

Why Bleomycin-Lipiodol?

Bleomycin damages the endothelial lining of the hemangioma's vascular channels, provoking fibrosis and shrinkage of the lesion over subsequent months, while lipiodol helps deliver and retain the drug selectively within the tumour's slow-flow vascular spaces. This targeted approach concentrates treatment within the hemangioma while sparing surrounding healthy liver tissue.

What the Evidence Shows

Large retrospective series have reported consistently strong results. In one study of 241 patients, embolization was technically successful in all cases, with 100% of patients reporting improvement in abdominal symptoms and the majority achieving more than 50% reduction in hemangioma size on follow-up imaging. Other large series specifically evaluating safety report 100% technical success rates and meaningful lesion coverage, with clinical success — defined as significant volume reduction — achieved in the large majority of treated patients.

What to Expect: Recovery and Side Effects

The most common side effect is post-embolization syndrome — a temporary combination of abdominal discomfort, low-grade fever, and fatigue that typically resolves within a few days as the body responds to the treated tissue. Average hospital stays in published series have been short, often under four days. Serious complications such as hepatic artery dissection or infection are uncommon and are actively monitored for during and after the procedure.

Embolization vs. Surgery

Surgical resection of giant hemangiomas can carry a meaningful risk of bleeding, particularly when lesions sit close to major portal or hepatic vessels, or when multiple lesions are present. Transarterial embolization avoids general surgery altogether, is performed through a tiny puncture, and allows most patients to return home within days — making it an increasingly preferred option for symptomatic giant hemangiomas that would otherwise require surgery.

The Bottom Line

For symptomatic giant liver hemangiomas, transarterial bleomycin-lipiodol embolization offers a well-evidenced, minimally invasive path to meaningful symptom relief and tumour shrinkage — with high technical success rates and a manageable safety profile reported across multiple large studies.